Print

Print


The Washington Post
Bush Stem Cell Policy Faces Criticism
By LAURA MECKLER
The Associated Press
Thursday, May 22, 2003; 6:11 PM

WASHINGTON - Researchers in Sweden are developing promising new
embryonic stem cell lines, a Senate panel heard Thursday, but
federally funded researchers in the United States will not be able to
use them because they were created after August 2001.

Leaders of the Senate panel that funds medical research said they
were outraged by the restrictions, but the head of the National
Institutes of Health maintained that science is not being hampered.

Sen. Arlen Specter, R-Pa., said he learned this week that four or
five cell lines have been recently developed in Sweden. Unlike lines
that are eligible for federal funding here, these have not been
contaminated with mouse cells used to spur their growth. That makes
them more valuable to U.S. researchers because there would fewer
questions about safety for humans, Specter said, arguing they should
be eligible for U.S. research dollars.

"The hands of the scientists shouldn't be tied in any way," said
Specter, chairman of the Senate Appropriations health subcommittee.
He said he was considering legislation to overturn President Bush's
August 2001 decision, which limited federal funding to stem cell
lines that were in existence at the time to discourage the
destruction of human embryos.

Stem cells are the building blocks for all body parts, immature cells
that go on to form organs and tissues. They form very early in an
embryo's development, present just days after fertilization.
Researchers hope to harness them to grow replacement tissues for
damaged organs and to cure disease.

Each stem cell line comes from a single embryo. Once fully developed,
it can reproduce indefinitely, allowing hundreds of researchers to
work with cells from a single line.

Gathering the valuable stem cells requires the destruction of the
embryo. Some consider this akin to destroying a life. Others argue
that these embryos, typically those leftover after fertility
treatments, are going to be thrown away anyway and using them for
research could help cure spinal cord injuries and diseases such as
Parkinson's and Alzheimer's.

Sen. Tom Harkin of Iowa, the top Democrat on the subcommittee, said
he was extremely frustrated that scientists are being "handcuffed,"
particularly given the large increases in NIH funding over the last
several years.

"Every time I see someone with Parkinson's, every time I see someone
with a spinal cord injury, or I see someone with Alzheimer's, I ask
the question: Why aren't we moving move aggressively on this?" Harkin
said.

NIH Director Elias Zerhouni downplayed the restrictions. He argued
that scientists have plenty of work to do with the stem cell lines
that are already eligible for funding. There are a total of 11 fully
developed lines available for research, he reported earlier this
month.

Specter honed in on the fact that all of them were grown using mouse
feeder cells, which may have contaminated them and could be a problem
in the future if the experiments are to be used to human treatments.
The Swedish lines, by contrast, did not use mouse cells.

Zerhouni responded that it's still unclear whether the Swedish lines
are viable since those researchers have not published their work yet
and it has not been reviewed by others. If they are, he said, then
the technique that they used could be applied to 16 lines that are
now frozen but were created before August 2001 and therefore eligible
for funding.

Harkin said it takes time to grow the cell lines and there's no
reason to duplicate the efforts of the Swedes. "You're wasting a
year, maybe a year and a half of time," he said.

Zerhouni said that the decision on what research to fund was based
not just on science but on "moral and ethical" considerations and
noted that private groups are free to fund research using new stem
cells.

The subcommittee also heard from outside researchers who were
critical of the Bush policy. Specter said he asked the NIH to
identify a nongovernment scientist who would testify in support of
the policy. NIH officials said they did not name one because they
could not find anybody willing to testify.

SOURCE: The Associated Press / The Washington Post
http://www.washingtonpost.com/wp-dyn/articles/A27642-2003May22.html

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn